
Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to AD, PsO, and HS.

Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to AD, PsO, and HS.

Test your knowledge on the foundation leading to the development of biologics to treat atopic dermatitis.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

Cheryl Burgess, MD, will share pearls on counseling patients on appropriate cosmetic procedures for their skin type, safety measures, and strategies to achieve desired outcomes.

The inaugural IDS meeting geared towards physician assistants and nurse practitioners begins the first day of Fall Clinical in Las Vegas.

Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.

One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.

Click here to answer if you're attending IDS 2023.

Founder Matthew Brunner MHS, PA-C, and Elevate Derm's leadership team explain why the meeting was founded in 2020 and its growth to fit today's treatment landscape.

Factors determining severe levels of stress included uncertainty about treatment progress, diagnosis, and treatment path.

Half of study participants achieved treatment success vs less than one-fourth with vehicle.

One of the many minds behind innovative Fall Clinical Dermatology sessions gives a sneak peek of the top 5 things to look forward to during this year's meeting.

Click here to answer if you're attending Fall Clinical.

Among the many sessions to be held at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.

October 6-12 was National Physician Assistant Week.

With October being National Eczema Awareness Month, there is robust research about the power of the microbiome and eczema.

Kwatra presented the abrocitinib data at EADV 2023.

Allergan Aesthetics recently announced the fifth-year of its partnership with Girls Inc. Nkem Ugonabo, MD, MPH, and Adelle Infante recently spoke with Dermatology Times to discuss the importance of STEM and dermatology mentorship.

While blue light irradiation was efficacious in reducing itch and IL-31 levels, it did not reduce any of the objective measures of AD.

Lindsey Zubritsky, MD, FAAD, discusses the importance of providing accurate eczema care education throughout the month of October.

This week’s collection of the latest dermatologic studies covers understanding the role of the skin microbiome in AD treatment, management of human hair follicle microbiome by a synthetic odorant, efficacy of tralokinumab in AD treatment, and considerations in geriatric dermatopathology.

Dupilumab’s efficacy was sustained through the 260-week open-label study.

Caregivers of children with AD also experience increased levels of stress, anxiety, depression, and suicidal ideation, extending the impact beyond the affected individual to their families.

In studying pediatric patients with skin of color in a center specializing in pigment and skin of color, investigators described a paucity of literature of such nature.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

Sometimes patients are unsure of what they can request from an employer for their skin conditions, and advice from a trusted clinician about reasonable accommodations can serve as an extra step to build their confidence to continue their career.

The advancement is based on previous observations of preliminary clinical efficacy. There are currently no FDA-approved therapies for this patient population.

Prepare your patients with helpful resources during National Eczema Awareness Month.